AZD9833 with palbociclib

DRUG2 trials

Sponsors

AstraZeneca

Conditions

ER+ HER2- Advanced Breast CancerER+, HER2-, Metastatic Breast Cancer

Phase 1

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Active, not recruitingNCT03616587

AstraZenecaER+ HER2- Advanced Breast Cancer

Start: 2018-10-11End: 2027-06-24Updated: 2026-08-18

AZD9833 China PK Study

CompletedNCT04818632

AstraZenecaER+, HER2-, Metastatic Breast Cancer

Start: 2021-11-12End: 2023-09-07Updated: 2024-12-17

Related Papers

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

2026-01-21

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

2025-10-011 citations

Abstract PS7-08: Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer

Clinical Cancer Research2025-06-13

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.

2024-05-0845 citations

Abstract PO3-19-09: SERENA-1: Results from a Phase 1 study (Parts I/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer

Cancer Research2024-05-025 citations

Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer

Cancer Research2023-03-0113 citations

Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Cancer Research2023-03-012 citations

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

Journal of Clinical Oncology2022-06-0140 citations

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Cancer Research2021-02-1532 citations

Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)

Cancer Research2021-02-154 citations

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

Cancer Research2020-08-1513 citations

Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833

Cancer Research2020-08-157 citations

Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

Cancer Research2020-08-151 citations

A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.

Journal of Clinical Oncology2020-05-2042 citations